JP3778453B2 - アポプトシス阻害剤 - Google Patents

アポプトシス阻害剤 Download PDF

Info

Publication number
JP3778453B2
JP3778453B2 JP52603195A JP52603195A JP3778453B2 JP 3778453 B2 JP3778453 B2 JP 3778453B2 JP 52603195 A JP52603195 A JP 52603195A JP 52603195 A JP52603195 A JP 52603195A JP 3778453 B2 JP3778453 B2 JP 3778453B2
Authority
JP
Japan
Prior art keywords
apo
compound
antibody
carrier
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP52603195A
Other languages
English (en)
Japanese (ja)
Other versions
JPH08511692A (ja
Inventor
クラマー，ペーター
ヴェステンドルプ，ミカエル
シェルツェオストフ，クラウス
デバーティン，クラウスミカエル
フランク，ライネル
ダイン，イェンス
ヴァルツァック，ヘニング
クニッピング，エカルト
ストリッケル，キルスティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19944412177 external-priority patent/DE4412177C1/de
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of JPH08511692A publication Critical patent/JPH08511692A/ja
Application granted granted Critical
Publication of JP3778453B2 publication Critical patent/JP3778453B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP52603195A 1994-04-08 1995-02-16 アポプトシス阻害剤 Expired - Lifetime JP3778453B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4412177.6 1994-04-08
DE19944412177 DE4412177C1 (de) 1994-04-08 1994-04-08 Hemmer von Apoptose
PCT/EP1995/000573 WO1995027735A1 (de) 1994-04-08 1995-02-16 Hemmer von apoptose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004064978A Division JP3811745B2 (ja) 1994-04-08 2004-03-09 アポトーシス阻害剤

Publications (2)

Publication Number Publication Date
JPH08511692A JPH08511692A (ja) 1996-12-10
JP3778453B2 true JP3778453B2 (ja) 2006-05-24

Family

ID=6514949

Family Applications (2)

Application Number Title Priority Date Filing Date
JP52603195A Expired - Lifetime JP3778453B2 (ja) 1994-04-08 1995-02-16 アポプトシス阻害剤
JP2004064978A Expired - Lifetime JP3811745B2 (ja) 1994-04-08 2004-03-09 アポトーシス阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004064978A Expired - Lifetime JP3811745B2 (ja) 1994-04-08 2004-03-09 アポトーシス阻害剤

Country Status (8)

Country Link
US (1) US20070207160A1 (enExample)
EP (1) EP0705278B1 (enExample)
JP (2) JP3778453B2 (enExample)
AT (1) ATE255129T1 (enExample)
DE (1) DE4447484C2 (enExample)
DK (1) DK0705278T3 (enExample)
ES (1) ES2211899T3 (enExample)
WO (1) WO1995027735A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE327258T1 (de) 1995-03-20 2006-06-15 Ko Okumura Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung
AU6091496A (en) * 1995-06-07 1996-12-30 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
US6096312A (en) * 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
DE19544333C2 (de) * 1995-11-28 1998-12-10 Deutsches Krebsforsch Verfahren zur Beurteilung der Aktivität von Arzneistoffen
AU2814897A (en) * 1996-04-25 1997-11-12 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
GB9703276D0 (en) * 1997-02-17 1997-04-09 Screaton Gavin R Materials and methods relating to the protection of useful immune cells
AU1288099A (en) * 1997-10-30 1999-05-24 Cornell Research Foundation Inc. A method of inhibiting an immune response to a recombinant vector
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
PT1606318E (pt) 2003-03-26 2009-11-10 Deutsches Krebsforsch Proteínas de fusão de fc melhoradas
SI2428252T1 (sl) 2006-12-28 2015-01-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Nevtralizacija invazije aktivnostnih blokov cd95 v celicah glioblastoma in vivo
EP2540740B1 (en) 2008-06-17 2014-09-10 Apogenix GmbH Multimeric TNF receptors
CN102497886B (zh) * 2009-07-21 2016-01-20 玛丽皇后与斯特菲尔德学院 用于细胞内药物递送的Fas(Apo-1，CD95)靶向平台
HUE029571T2 (en) 2012-07-18 2017-03-28 Apogenix Ag Inhibitors of the CD95 signaling pathway for treating MDS
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US20200121719A1 (en) 2017-01-06 2020-04-23 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
CA3062874A1 (en) 2017-05-10 2018-11-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
CA3083118A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
JP7565795B2 (ja) 2017-12-15 2024-10-11 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
AU2020233284A1 (en) 2019-03-01 2021-09-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
BR112021019328A2 (pt) 2019-03-29 2021-11-30 Myst Therapeutics Llc Métodos ex vivo para produzir um produto terapêutico de célula t e composições e métodos relacionados
CA3162703A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
AU2021226903A1 (en) 2020-02-27 2022-10-20 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive T cells and related compositions thereof
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
PT90657B (pt) * 1988-05-27 1995-03-01 Ortho Pharma Corp Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
EP0522081A4 (en) * 1990-03-30 1993-06-16 Smithkline Beecham Corporation Inhibition of disease associated with immunodeficiency virus infection
EP0510691B1 (en) * 1991-04-26 2004-11-03 Osaka Bioscience Institute DNA coding for human cell surface antigen
NZ275711A (en) * 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof

Also Published As

Publication number Publication date
DE4447484C2 (de) 1997-07-17
WO1995027735A1 (de) 1995-10-19
ES2211899T3 (es) 2004-07-16
JP2004215669A (ja) 2004-08-05
EP0705278A1 (de) 1996-04-10
US20070207160A1 (en) 2007-09-06
JPH08511692A (ja) 1996-12-10
DE4447484A1 (de) 1995-10-26
JP3811745B2 (ja) 2006-08-23
DK0705278T3 (da) 2004-03-22
EP0705278B1 (de) 2003-11-26
ATE255129T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
JP3778453B2 (ja) アポプトシス阻害剤
AU755794B2 (en) Interleukin-18 binding proteins, their preparation and use
Madry et al. The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily.
CA2067031C (en) Dna coding for human cell surface antigen
KR100244960B1 (ko) 인간 수용체 h4-1bb
US7638281B2 (en) Polypeptide, cDNA encoding the same and use of them
US7875709B2 (en) Nucleic acids encoding interleukin-18 mutants
JP4180114B2 (ja) Ｔｎｆ受容体関連因子（ｔｒａｆ）のモジュレーター、その製造法および使用
JP2001017191A (ja) 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
JPH02288898A (ja) ヒトｂ細胞刺激因子２レセプター蛋白質
Mori et al. Cloning and sequence analysis of a cDNA for lymphocyte proliferation potentiating factor of rabbit polymorphonuclear leukocytes: Identification as rabbit interleukin 1β
KR20000075749A (ko) 신규의 폴리펩티드, 그 폴리펩티드를 암호하는 ｄｎａ 및 그용도
Tiefenthaler et al. M1204, a novel 2′, 5′ oligoadenylate synthetase with a ubiquitin-like extension, is induced during maturation of murine dendritic cells
BG64799B1 (bg) Саsн (хомолог на каспаза) със смъртоносен ефекторен домен и модулатори на функцията на fаs рецептори
EP1077259A1 (en) NOVEL POLYPEPTIDES, cDNAS ENCODING THE SAME AND UTILIZATION THEREOF
EP1027436A1 (en) Viral encoded semaphorin protein receptor dna and polypeptides
AU2003200442B2 (en) Interleukin-18 binding proteins, their preparation and use
JP4010606B2 (ja) ポリペプチドの製造方法
KR20040009997A (ko) 직렬 연쇄체를 갖는 면역접합체
JPH07505051A (ja) Ｈｉｖ−１ｅｎｖ及びｎｅｆタンパク質に対して局部的相同性を有するタンパク質，ａａｍｐ−１
EP1394184A1 (de) Hemmer von Apoptose
JPH08301898A (ja) 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物
JP2001523102A (ja) アポトーシス細胞死経路の細胞内変調因子
JP2000236884A (ja) ペプチド
JPH1014581A (ja) ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするｄｎａ断片

Legal Events

Date Code Title Description
A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20031209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040309

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050613

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20050728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060224

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090310

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100310

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110310

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110310

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120310

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130310

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130310

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140310

Year of fee payment: 8

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term